AAAAAA
Results: 26-42/42
Authors:
Wuchter, C
Karawajew, L
Ruppert, V
Schrappe, M
Harbott, J
Ratei, R
Dorken, B
Ludwig, WD
Citation: C. Wuchter et al., Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to inductionchemotherapy and relapse rate in childhood acute lymphoblastic leukaemia, BR J HAEM, 110(1), 2000, pp. 154-160
Authors:
Karawajew, L
Ruppert, V
Wuchter, C
Kosser, A
Schrappe, M
Dorken, B
Ludwig, WD
Citation: L. Karawajew et al., Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with Bcl-2up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T-cell acute lymphoblastic leukemia, BLOOD, 96(1), 2000, pp. 297-306
Authors:
Reiter, A
Schrappe, M
Ludwig, WD
Tiemann, M
Parwaresch, R
Zimmermann, M
Schirg, E
Henze, G
Schellong, G
Gadner, H
Riehm, H
Citation: A. Reiter et al., Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Groupreport, BLOOD, 95(2), 2000, pp. 416-421
Authors:
Schrappe, M
Reiter, A
Ludwig, WD
Harbott, J
Zimmermann, M
Hiddemann, W
Niemeyer, C
Henze, G
Feldges, A
Zintl, F
Kornhuber, B
Ritter, J
Welte, K
Gadner, H
Riehm, H
Citation: M. Schrappe et al., Improved outcome in childhood acute lymphoblastic leukemia despite reduceduse of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90, BLOOD, 95(11), 2000, pp. 3310-3322
Authors:
Schwartz, S
Heinecke, A
Zimmermann, M
Creutzig, U
Schoch, C
Harbott, J
Fonatsch, C
Loffler, H
Buchner, T
Ludwig, WD
Thiel, E
Citation: S. Schwartz et al., Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance, LEUK LYMPH, 34(1-2), 1999, pp. 85-94
Authors:
Kafer, G
Willer, A
Ludwig, WD
Kramer, A
Hehlmann, R
Hastka, J
Citation: G. Kafer et al., Intracellular expression of CD61 precedes surface expression, ANN HEMATOL, 78(10), 1999, pp. 472-474
Authors:
Stroszczynski, C
Hosten, N
Oellinger, J
Spahn, G
Amthauer, H
Bittner, RC
Hierholzer, J
Ludwig, WD
Felix, R
Citation: C. Stroszczynski et al., Malignant lymphoma: MR tomographic findings of residual mediastinal space-occupying lesions., ROFO-F RONT, 171(3), 1999, pp. 192-199
Authors:
Reinhardt, P
Maschmeyer, G
Schulze, G
Fleischer, C
Ellerbrok, H
Schlegelberger, B
Stein, H
Pauli, G
Ludwig, WD
Citation: P. Reinhardt et al., First non-imported HTLV-1 positive adult T cell leukemia/lymphoma (ATLL) in Germany, LEUKEMIA, 13(8), 1999, pp. 1296-1297
Authors:
Langerak, AW
Wolvers-Tettero, ILM
van den Beemd, MWM
van Wering, ER
Ludwig, WD
Hahlen, K
Necker, A
van Dongen, JJM
Citation: Aw. Langerak et al., Immunophenotypic and immunogenotypic characteristics of TCR gamma delta(+)T cell acute lymphoblastic leukemia, LEUKEMIA, 13(2), 1999, pp. 206-214
Authors:
Wuchter, C
Karawajew, L
Ruppert, V
Buchner, T
Schoch, C
Hafelach, T
Ratei, R
Dorken, B
Ludwig, WD
Citation: C. Wuchter et al., Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics, LEUKEMIA, 13(12), 1999, pp. 1943-1953
Authors:
Bene, MC
Bernier, M
Castoldi, G
Faure, GC
Knapp, W
Ludwig, WD
Matutes, E
Orfao, A
van't Veer, M
Citation: Mc. Bene et al., Impact of immunophenotyping on management of acute leukemias, HAEMATOLOG, 84(11), 1999, pp. 1024-1034
Authors:
Stroszczynski, C
Oellinger, J
Hosten, N
Spahn, G
Amthauer, H
Ricke, J
Hoffmann, KT
Eichstaedt, H
Ludwig, WD
Felix, R
Citation: C. Stroszczynski et al., Staging and monitoring of malignant lymphoma of the bone: Comparison of Ga-67 scintigraphy and MRI, J NUCL MED, 40(3), 1999, pp. 387-393
Authors:
Dordelmann, M
Reiter, A
Borkhardt, A
Ludwig, WD
Gotz, N
Viehmann, S
Gadner, H
Riehm, H
Schrappe, M
Citation: M. Dordelmann et al., Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia, BLOOD, 94(4), 1999, pp. 1209-1217
Authors:
Reiter, A
Schrappe, M
Tiemann, M
Ludwig, WD
Yakisan, E
Zimmermann, M
Mann, G
Chott, A
Ebell, W
Klingebiel, T
Graf, N
Kremens, B
Muller-Weihrich, S
Pluss, HJ
Zintl, F
Henze, G
Riehm, H
Citation: A. Reiter et al., Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90, BLOOD, 94(10), 1999, pp. 3294-3306
Authors:
Buchner, T
Wormann, B
Loffler, H
Gassmann, W
Haferlach, T
Fonatsch, C
Haase, D
Schoch, C
Hossfeld, D
Lengfelder, E
Aul, C
Heyll, A
Maschmeyer, G
Ludwig, WD
Sauerland, MC
Heinecke, A
Citation: T. Buchner et al., Double induction strategy for acute myeloid leukemia: The effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: A randomized trial by the German AML Cooperative Group, BLOOD, 93(12), 1999, pp. 4116-4124
Authors:
Schwartz, S
Behre, G
Heinemann, V
Wandt, H
Schilling, E
Arning, M
Trittin, A
Kern, WV
Boenisch, O
Bosse, D
Lenz, K
Ludwig, WD
Hiddemann, W
Siegert, W
Beyer, J
Citation: S. Schwartz et al., Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: Results of a prospective randomized multicenter trial, BLOOD, 93(11), 1999, pp. 3654-3661
Authors:
Brach, MA
Buhring, HJ
Gruss, HJ
Ashman, LK
Ludwig, WD
Mertelsmann, RH
Herrmann, F
Citation: Ma. Brach et al., Functional expression of c-kit by acute myelogenous leukemia blasts is enhanced by tumor necrosis factor-alpha through posttranscriptional mRNA stabilization by a labile protein (Retraction of vol 80, pg 1224, 1992), BLOOD, 93(10), 1999, pp. 3573-3573